CHD/Prevention News

After decades of research, pharmacologic treatment of obesity gained significant traction with the launch of GLP-1 receptor agonists, and several potentially more potent drugs are currently in the pipeline, a speaker reported.

Childhood BMI, blood pressure and smoking status performed as well as lipid levels in predicting the risk for cardiovascular events in adulthood, according to study findings published in Pediatrics.

Five years after receiving a complete response letter from the agency, Lexicon Pharmaceuticals brought sotagliflozin back before an FDA advisory panel to seek an indication to treat patients with type 1 diabetes and chronic kidney disease.

BOSTON — Behavioral modification with diet and exercise demonstrated similar weight-loss benefits vs. other pharmaceutical and surgical approaches to obesity management, but patients must remain adherent, a speaker reported.

Daylight saving time has been a source of contention and debate since its introduction in 1918.

Among patients with obesity undergoing bariatric surgery, the proportion taking a GLP-1 receptor agonist in the year before their procedure rose sharply between 2018 and 2023, researchers reported.

BOSTON — Addiction to ultraprocessed food may be diagnosed similarly to other substance use disorders, and reducing stigma and tailored treatment are both important to improving cardiometabolic health, a speaker reported.

In patients with type 2 diabetes, semaglutide was associated with a significantly lower risk for an Alzheimer’s disease diagnosis within 3 years compared with other diabetes medications, according to a study published in Alzheimer’s & Dementia.

BOSTON — In this Healio video exclusive, Virend K. Somers, MD, PhD, discusses his presentation at the Cardiometabolic Health Congress, “Sleep Disorders and Cardiometabolic Health.”